MABT95
Anti-Arp2/3 complex Antibody, clone 13C9
clone 13C9, from mouse
Synonym(s):
Actin-related protein 2/3 complex subunit 3, Arp2/3 complex 21 kDa subunit, p21-ARC
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
13C9, monoclonal
species reactivity
human
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... ARPC3(10094)
General description
The Arp2/3 complex, which contains ARP2, ARP3, ARPC1B/p41-ARC, ARPC2/p34-ARC, ARPC3/p21-ARC, ARPC4/p20-ARC and ARPC5/p16-ARC, plays a major role in the regulation of the actin polymerization in the cytoskeleton. Two of complex′s seven subunits (ARP2 and ARP3) closely resemble monomeric actin and serve as nucleation sites for new actin filaments. The Arp2/3 complex works in conjunction with an activating nucleation-promoting factor (NPF) to aid in the formation of branched actin networks. The regulation of actin cytoskeleton reorganization is important for processes like cell migration, phagocytosis, and intracellular motility of lipid vesicles.
Immunogen
GST-tagged recombinant protein corresponding to human Arp2/3 complex.
Application
Anti-Arp2/3 complex Antibody, clone 13C9 detects level of Arp2/3 complex & has been published & validated for use in WB, IH(P).
Immunohistochemistry Analysis: A 1:5,000 dilution from a representative lot detected Arp2/3 complex in human colorectal cancer and human colon tissues (antibody may need further dilution if staining is too strong - optimal dilution to be determined by the end user).
Research Category
Cell Structure
Cell Structure
Research Sub Category
Cytoskeleton
Cytoskeleton
Quality
Evaluated by Western Blot in MCF-7 cell lysate.
Western Blot Analysis: A 1:5,000 dilution of this antibody detected Arp2/3 complex on 10 µg of MCF-7 cell lysate.
Western Blot Analysis: A 1:5,000 dilution of this antibody detected Arp2/3 complex on 10 µg of MCF-7 cell lysate.
Target description
~20 kDa observed
Physical form
Format: Purified
Protein G Purified
Purified mouse monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Control
MCF-7 cell lysate
MCF-7 cell lysate
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Miran Rada et al.
Cancers, 14(5) (2022-03-11)
Vessel co-option is correlated with resistance against anti-angiogenic therapy in colorectal cancer liver metastases (CRCLM). Vessel co-opting lesions are characterized by highly motile cancer cells that move toward and along the pre-existing vessels in the surrounding nonmalignant tissue and co-opt
Sophia Frentzas et al.
Nature medicine, 22(11), 1294-1302 (2016-11-01)
The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the nonangiogenic mechanism of vessel co-option. Here we show that vessel
Miran Rada et al.
Cancers, 14(10) (2022-05-29)
Resistance to anti-angiogenic therapy is a major challenge in the treatment of colorectal cancer liver metastases (CRCLMs). Vessel co-option has been identified as a key contributor to anti-angiogenic therapy resistance in CRCLMs. Recently, we identified a positive correlation between the
Aida M Lopez-Guerrero et al.
Scientific reports, 10(1), 6580-6580 (2020-04-22)
Tumor invasion requires efficient cell migration, which is achieved by the generation of persistent and polarized lamellipodia. The generation of lamellipodia is supported by actin dynamics at the leading edge where a complex of proteins known as the WAVE regulatory
Diana C Muñoz-Lasso et al.
Scientific reports, 10(1), 5207-5207 (2020-04-07)
Abnormalities in actin cytoskeleton have been linked to Friedreich's ataxia (FRDA), an inherited peripheral neuropathy characterised by an early loss of neurons in dorsal root ganglia (DRG) among other clinical symptoms. Despite all efforts to date, we still do not
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service